PE-22-28
PE-22-28
A synthetic peptide derived from Spadin that acts as a TREK-1 channel blocker. Investigated for rapid antidepressant effects similar to ketamine but without dissociative properties.
Typical Cost
$60-150/vial (10mg)
Status
Research
Peptide Profile
PE-22-28
Mechanism of Action
Blocks TREK-1 potassium channels, leading to increased neuronal excitability and enhanced neuroplasticity. Similar mechanism to ketamine's antidepressant effects but more targeted.
Common Dosages
intranasal
10-100mcg
Daily · 2-4 weeks
Benefits
Rapid antidepressant effects
Enhanced neuroplasticity
Improved mood
No dissociation
Non-addictive
Side Effects
Unknown long-term effects
Headache
Nasal irritation
Mild stimulation
Key Research
PE-22-28 antidepressant effects in rodents
Demonstrated rapid onset antidepressant effects in animal models within hours
Regulatory Status
Preclinical research only. Not FDA-approved. No human trials completed.
Contraindications
- ⚠Pregnancy/breastfeeding
- ⚠Bipolar disorder
- ⚠Active suicidal ideation
GLP-1 users experiencing mood changes during weight loss should consult healthcare providers. SeraVia offers foundational wellness support.
Learn More →Find peptide providers
Search 18,000+ clinics offering peptide therapy alongside GLP-1 medications.
Search Providers →Disclaimer: This information is for educational and research purposes only. Peptides described here may not be FDA-approved for human use. Always consult a qualified healthcare provider before using any peptide product. GLP1Search does not sell peptides.